Volume 1.26 | Nov 30

Newsletter Issue
Dermal Cell News 1.26 November 30, 2015
Dermal Cell News
     In this issue: Publications | Reviews | Science News | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  DCN on Twitter
Scientists Identify Promising New Melanoma Drug
A new drug may show promise for treating skin cancers that are resistant or unresponsive to today’s leading therapies. The new compound, named SBI-756, targets a specific molecular machine known as the translation initiation complex. [Press release from Sanford Burnham Prebys Medical Discovery Institute discussing online prepublication in Cancer Research] Press Release | Abstract
PUBLICATIONS (Ranked by impact factor of the journal)

Injectable and Thermosensitive Soluble Extracellular Matrix and Methylcellulose Hydrogels for Stem Cell Delivery in Skin Wounds
Scientists report a thermosensitive hydrogel composed of soluble extracellular matrix and methylcellulose for injectable stem cell delivery. [Biomacromolecules] Abstract

S100A8 and S100A9 Are Induced by Decreased Hydration in the Epidermis and Promote Fibroblast Activation and Fibrosis in the Dermis
The authors showed that reduced hydration increases the expression of S100 protein family members, S100A8/S100A9, in stratified keratinocyte culture and human ex vivo skin culture. [Am J Pathol] Abstract

Platelets Regulate the Migration of Keratinocytes via Podoplanin/CLEC-2 Signaling during Cutaneous Wound Healing in Mice
Investigators evaluated the effect of podoplanin expression levels on keratinocyte motility using cultured primary normal human epidermal keratinocytes. [Am J Pathol] Abstract

A Comparative Analysis of Gene Expression Profiles during Skin Regeneration in Mus and Acomys
Scientists performed an extensive comparison of gene expression profiles in response to 8mm full-thickness excisional wounds at days 3, 5, 7 and 14 post-wounding between Acomys and Mus to characterize differences in wound healing, and identify mechanisms involved in scar-free healing. [PLoS One] Full Article

Effect of Microtubule-Associated Protein-4 on Epidermal Cell Migration under Different Oxygen Concentrations
The authors showed that under hyperoxic and hypoxic conditions, HaCaT cells were able to regulate cell microtubule dynamics by microtubule-associated protein (MAP4), thus promoting cell migration. MAP4 silencing through targeted shRNA attenuated HaCaT cell migration under the above oxygen concentrations. [J Dermatol] Abstract


Strand-Specific In Vivo Screen of Cancer-Associated miRNAs Unveils a Role for miR-21 in SCC Progression
Focusing on miRs and/or miRs abundant in squamous cell carcinoma (SCC) stem cells, researchers engineered an efficient, strand-specific expression library, and apply functional genomics screening in mice to identify which of 169 cancer-associated miRs are key drivers in malignant progression. [Nat Cell Biol] Abstract

Hydrogen Sulfide-Induced Itch Requires Activation of Cav3.2 T-Type Calcium Channel in Mice
Researchers investigated the roles of hydrogen sulfide (H2S), a ubiquitous gasotransmitter, in itch signaling. They found that intradermal injection of H2S donors NaHS or Na2S, but not GYY4137, dose-dependently induced scratching behavior in a μ-opioid receptor-dependent and histamine-independent manner in mice. [Sci Rep] Full Article

Impact of Oncogenic BRAF Mutations and p16 Expression on the Growth Rate of Early Melanomas and Nevi In Vivo
The expression of BRAFV 600E and the loss of p16 accelerated the growth rate of early melanomas in vivo but not in melanocytic nevi. [Br J Dermatol] Abstract

IκBζ: A Key Protein in the Pathogenesis of Psoriasis
The author discusses the recent findings demonstrating that IκBζ, a transcriptional co-activator, plays a crucial role in the development of psoriasis by mediating IL-17A-driven effects. [Cytokine] Abstract

Visit our reviews page to see a complete list of reviews in the dermal cell research field.
Merck Announces Initial Results for KEYTRUDA® (Pembrolizumab) with Novel Immunotherapy Combinations from Three Investigational Studies Presented
Merck announced findings from three studies investigating the use of KEYTRUDA®, the company’s anti-PD-1 therapy, in combination with three other immunotherapies – epacadostat, IMLYGICTM, and ipilimumab – in patients with advanced melanoma. [Press release from Merck & Co., Inc. discussing research presented at the 12th International Congress of the Society for Melanoma Research (SMR), San Francisco] Press Release

From our sponsor: Learn about detecting cancer stem cells with ALDEFLUOR™. Watch the webinar.
Exelixis Announces European Commission Approval of COTELLIC™ (Cobimetinib) for Use in Combination with Vemurafenib in Advanced BRAF V600 Mutation-Positive Melanoma
Exelixis, Inc. announced that the European Commission has approved COTELLIC™ for use in combination with vemurafenib for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation. [Exelixis, Inc.] Press Release

Bristol-Myers Squibb Announces U.S. Food and Drug Administration Approval for Opdivo (Nivolumab) as a Single Agent for the Treatment of Patients with Previously Untreated BRAF Wild-Type Advanced Melanoma
Bristol-Myers Squibb Company announced that the U.S. Food and Drug Administration has approved Opdivo injection, for intravenous use, as a single agent for the treatment of patients with BRAF V600 wild-type unresectable or metastatic melanoma. [Bristol-Myers Squibb Company] Press Release
National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
NEW 28th Lorne Cancer Conference
February 11-13, 2016
Lorne, Australia

Visit our events page to see a complete list of events in the dermal cell community.
NEW Postdoctoral Researcher – Non-Coding RNAs and Skin Wound Healing (Karolinska Institutet)

Research Associate/Scientist – Dermato-Pharmacokinetics (Simcyp)

Senior Manager – Immunology (Baxalta Innovations GmbH)

Team Leader/Professor/Associate Professor – Regenerative Medicine (Ji Nan University)

Research Faculty and Associates – Dermatology (University of Pittsburgh)

Postdoctoral Position – Genetic Skin Diseases (Inserm)

Postdoctoral Associate – Dermatology (University of Pittsburgh)

Research Technician II – Stem Cell and Gene Therapy (Fred Hutchinson Cancer Research Center)

Postdoctoral Position – Tissue Engineering and Regenerative Medicine (Northwestern University)

Independent Junior Group Leader – Human Genetics of Inflammatory Skin Diseases (University of Lübeck)

Recruit Top Talent: Reach more than 60,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Dermal Cell News? Click here to submit!

Comments or suggestions? Submit your feedback here
Learn more about Dermal Cell News: Archives | Events | Contact Us